Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity

[1]  A. Nagler,et al.  Allogeneic hematopoietic stem-cell transplantation in patients with acute myeloid leukemia in first complete remission: new answers for an old question , 2005, Leukemia.

[2]  D. Blaise,et al.  The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison , 2005, Leukemia.

[3]  J. Briones,et al.  Conventional versus reduced‐intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies , 2005, European journal of haematology.

[4]  R. Storb,et al.  Low-intensity allogeneic hematopoietic stem cell transplantation for myeloid malignancies: separating graft-versus-leukemia effects from graft-versus-host disease , 2005, Current opinion in hematology.

[5]  J. Gribben,et al.  Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. , 2004, Blood.

[6]  M. Munsell,et al.  Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. , 2004, Blood.

[7]  P. Thall,et al.  Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. , 2004, Blood.

[8]  A. Nagler,et al.  Clinical Implications of Minimal Residual Disease Monitoring for Stem Cell Transplantation after Reduced Intensity and Nonmyeloablative Conditioning , 2004, Acta Haematologica.

[9]  K. Cleary,et al.  Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  H. Deeg,et al.  Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. , 2003, Blood.

[11]  M. Maris,et al.  Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. , 2003, Blood.

[12]  W. Siegert,et al.  Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor , 2003, Bone Marrow Transplantation.

[13]  T. Gooley,et al.  Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. , 2003, Blood.

[14]  J. Sierra,et al.  Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. , 2002, Blood.

[15]  P. Thall,et al.  Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  J Wagner,et al.  Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. , 2001, Blood.

[17]  P. Thall,et al.  Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. , 2001, Blood.

[18]  N. Ueno,et al.  Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. , 2000, British journal of haematology.

[19]  J. Sierra,et al.  Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience , 2000, Bone Marrow Transplantation.

[20]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[21]  A. Nagler,et al.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.

[22]  S. Forman.  Stem cell transplantation in acute leukemia , 1998, Current opinion in oncology.

[23]  E. Estey,et al.  Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. , 1997, Blood.

[24]  J. Ferrara,et al.  Cytokine dysregulation and acute graft-versus-host disease. , 1992, Blood.

[25]  F. Appelbaum,et al.  Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. , 1990, Blood.

[26]  L. Grochow,et al.  VENOOCCLUSIVE DISEASE OF THE LIVER FOLLOWING BONE MARROW TRANSPLANTATION , 1987, Transplantation.

[27]  R. Gale,et al.  HOW DOES BONE-MARROW TRANSPLANTATION CURE LEUKAEMIA? , 1984, The Lancet.

[28]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[29]  N. Kröger,et al.  Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age>55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning , 2005, Leukemia.

[30]  A. Nagler,et al.  Nonmyeloablative stem cell transplantation: lessons from the first decade of clinical experience. , 2004, Current hematology reports.

[31]  A. Nagler,et al.  Non-myeloablative stem cell transplantation (NST): chimerism testing as guidance for immune-therapeutic manipulations , 2001, Leukemia.

[32]  T. D. de Witte.  Stem cell transplantation in myelodysplastic syndromes. , 1999, Forum.

[33]  R. Brereton.  Letter: Treatment of spina bifida. , 1975, Lancet.